First independent observations, presented by Dr. Leon Au, leading consultant ophthalmology and eye surgeon, during ICGS 2024 in Abu Dhabi, underscore CID’s strong potential as treatment option for glaucoma.
Second-generation CID (Cilioscleral Interpositioning Device) makes cilioscleral surgical procedure, which leaves anterior chamber of eye untouched, less invasive and easier to perform.
You will be responsible for managing and adapting the quality system to meet the various standards required for international commercialization (ISO 13485, MDR 2017/745, MDSAP, FDA 21 CFR 820...), as well as preparing the necessary documentation for registrations outside Europe...
Primary angle-closure glaucoma (PACG) represents a significant cause of blindness, affecting more than 17 million people worldwide. Moreover, the currently available treatment options for the management PACG remain relatively limited. The cilioscleral inter-positioning device is a novel minimally invasive implant designed to increase uveoscleral outflow without entering the chamber. This unique approach to lower IOP represents a new, efficient, and safe surgical option to reduce intraocular pressure for patients with PACG.
At the World Glaucoma Congress (WGC) in Rome, Italy this summer, Ciliatech presented preliminary results of the second 2-year postoperative clinical trial (SAFARI Ⅱ) on its Cilioscleral Interposition Device (CID).
Glaucoma is a group of progressive, neurodegenerative eye diseases associated with irreversible optic neuropathy followed by visual-field impairment. Epidemiological estimates suggest that the most common form,
Results from second CID (Cilio-scleral Interposition Device) study confirm sustained decrease in intraocular pressure (IOP), while preserving anterior chamber of eye